 Immune checkpoint inhibitor, ICI, therapy has been shown to be effective in treating various types of cancer. However, it can also cause a range of immune-related adverse events, erase, which have become increasingly prevalent with the introduction of newer ICI agents. These include skin, gastrointestinal, endocrine, neurological, hematologic, renal, and urinary system complications. Clinicians must be aware of these potential side effects and know how to identify them early so they can be managed effectively. Additionally, there is a need for better biomarkers to predict the onset of erase, as well as prophylactic measures to prevent them from occurring. This article was authored by Vivek Kumar, Neha Chaudhary, Mohit Garg, and others.